Search results
Dow Jones Cuts Gains After Hot Inflation Data; Nvidia Rallies On Strong TSMC Sales
Investor's Business Daily· 1 hour agoChipotle and Merck featured in this Stocks Near A Buy Zone column. An essential resource for daily...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 4 hours agoBy buying an index fund, investors can approximate the average market return. But if you pick the...
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks via Yahoo Finance· 1 day agoMerck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good...
Merck's endometrial cancer therapy fails trial
Reuters via Yahoo News· 1 day agoThe drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after...
Merck’s trial of KEYTRUDA regimen fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 6 hours agoMerck has announced that its Phase III KEYNOTE-B21 (ENGOT-en11/GOG-3053) clinical trial of KEYTRUDA...
Merck treatment for a type of uterus cancer fails trial
Reuters via Yahoo Finance· 1 day agoMay 9 (Reuters) - Merck said on Thursday its treatment for a type of uterus cancer did not meet the main goal of disease-free survival in a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Data-Based Insights About Merck & Co Inc
Stocks Register· 1 day agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $129.66. A look ...
Dow Jones Drug Giant Merck, Nvidia Eye Buy Points In Current Stock Market
Investor's Business Daily· 4 days agoAmong the best stocks to watch, Dow Jones drug giant Merck, Nvidia, Chipotle Mexican Grill and NXP...
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
Market Watch· 1 day agoMerck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with chemotherapy to ...
Merck First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 4 days agoMerck (NYSE:MRK) First Quarter 2024 Results Key Financial Results Revenue: US$15.8b (up 8.9% from 1Q...
